{"entity":{"id":"nct06118788","kind":"trial","name":"Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","aka":[],"tldr":"A phase 1/2 trial of BG1805 in acute myeloid leukaemia, run by Guangzhou Bio-gene Technology Co., Ltd, now recruiting.","summary":"Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT06118788 by Guangzhou Bio-gene Technology Co., Ltd, with 24 participants planned, started 2024-03-07 and due to reach its primary completion in 2027-03. Interventions recorded: BG1805.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06118788","url":"https://clinicaltrials.gov/study/NCT06118788"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06118788","phase":"1/2","setting":"A Single-arm, Dose-escalation and Dose-expansion Phase I Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","sponsor":"Guangzhou Bio-gene Technology Co., Ltd","enrolled":24,"outcomes":[]},"route":"/trials/nct06118788/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}]}}